Peptide record

TPDB91796

Tempoprin-1CEa Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity modified_plain modified
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91796
Tempoprin-1CEa
Anti-inflammatory Antibacterial Anticancer Antifungal Antiparasitic Antiviral Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Immunity and inflammation peptides Toxicity and safety peptides
Peptipedia AntiBP3 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF Antifungipept APD_complete HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
modified_plain
Yes
A 15-aa modified multi-activity (Anti-inflammatory, Antibacterial, Anticancer, and other sources) peptide sequence curated from Peptipedia, AntiBP3, AntiCP 2.0, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FVDLKKIANIINSIF-NH2
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
15 reviewed residue count
Amidation Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Chinese brown frog Rana chensinensis. Activity
Evidence Records 7 records
Evidence 1 Activity

Activity

22% Cell viability at 40 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

61% Cytotoxicity at 40 µM
Anticancer

Target

Breast Cancer
MDA-MB-231
Breast

Assay & Model

LDH leakage assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 3 Activity

Activity

61% Cell viability at 40 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 4 Activity

Activity

32% Cytotoxicity at 40 µM
Anticancer

Target

Breast Cancer
MCF-7
Breast

Assay & Model

LDH leakage assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2012
Evidence 5 Activity

Activity

70% Cell viability at 20 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

45% Cell viability at 30 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

30 % Cell viability at 40 µM
Anticancer

Target

Breast Cancer
Bcap-37
Breast

Assay & Model

MTT/MTS assay
1-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013